Inhibitors of SARM1

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein
• R1 is selected from —CN, and —CON(R)2;
• R2 is selected from —H and —CH3;
• R3 is -Cy1;
• R4 is -Cy2;
• Cy1 is selected from
• each Rx is independently selected from halogen, —OR, —C(O)R, and C1-6 aliphatic optionally substituted with halogen;
• Cy2 is selected from phenyl, a 3- to 7-membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7- to 9-membered bridged bicyclic or spirocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8- to 10-membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein each phenyl, heterocyclic, and heteroaryl ring is substituted with 0-4 Rv;
• each Rv is independently selected from halogen, —CN, —NO2, —SR, —N(R)2, —OR, —C(O)R, —SO2R, —CO2R, —SO2N(R)2, —CON(R)2, —N(R)SO2R, —N(R)C(O)R, C1-6 aliphatic optionally substituted with halogen, and 5- to 6-membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur optionally substituted with halogen;
• and
• each R is independently hydrogen or C1-6 aliphatic optionally substituted with halogen, or:
• two instances of R, together with the atom to which they are attached, form a 3- to 6-membered saturated or partially unsaturated heterocyclic ring.